- 1 Title page
- 2 Manuscript title: Cost-effectiveness analysis of COVID-19 mRNA XBB.1.5 Fall 2023 vaccination in the
- 3 Netherlands
- 4 Authors
- 5 Florian Zeevat, PhD^{1,2}, Simon van der Pol, PharmD, PhD^{1,2}, Tjalke Westra, PhD⁴, Ekkehard Beck, PhD⁵,
- 6 Maarten J. Postma, PhD^{1,2,3}, Cornelis Boersma, PhD^{1,2,6}
- 7 1. Health-Ecore, Zeist, the Netherlands
- University of Groningen, University Medical Center Groningen, Department of Health Sciences,
 Groningen, the Netherlands
- 10 3. University of Groningen, Department of Economics, Econometrics & Finance, Groningen, the
- 11 Netherlands
- 12 4. Moderna Netherlands, Amsterdam, the Netherlands
- 13 5. Moderna Inc, Cambridge, MA, USA
- 14 6. Open University, Department of Management Sciences, Heerlen, the Netherlands
- 15
- 16 Corresponding author
- 17 Florian Zeevat, Health-Ecore, Utrechtseweg 60, 3704 HE Zeist, the Netherlands, email:
- 18 florianzeevat@health-ecore.com

19

21 Abstract

Objective: This study aims to assess the cost-effectiveness of the Fall 2023 COVID-19 mRNA XBB.1.5
vaccination campaign in the Netherlands, comparing the XBB1.5 updated mRNA-1273.222 with the XBB1.5
updated BNT162b2 vaccine.

Methods: A one-year decision tree-based cost-effectiveness model was developed, considering three scenarios: no Fall 2023 vaccination, BNT162b2 vaccination and mRNA-1273 vaccination in the COVID-19 high-risk population in the Netherlands. The high-risk population includes everyone of 60 and older, and younger adults at high risk as identified by the Dutch Health Council. Costs were included from a societal perspective and the modelled period started in October 2023 and ended in September 2024, including life years lost with a lifetime horizon. Sensitivity and scenario analyses were conducted to evaluate model robustness.

32 Results: In the base case, mRNA-1273 demonstrated substantial benefits over BNT162b2, potentially

33 averting 20,629 symptomatic cases, 924 hospitalizations (including 32 ICU admissions), 207 deaths, and

2,124 post-COVID cases. Societal cost savings were €12.9 million (excluding vaccination costs), with 1,506

35 QALYs gained. The break-even incremental price of mRNA-1273 compared to BNT162b2 was €16.72 or

36 €34.32 considering a willingness to pay threshold (WTP) of 20,000 or 50,000 euro per QALY gained.

Conclusion: This study provides a comprehensive cost-effectiveness analysis supporting the adoption of the
mRNA-1273 vaccine in the national immunization programme in the Netherlands, provided that the Dutch
government negotiates a vaccine price that is at most €34.32 per dose higher than BNT162b2. Despite
limitations, the findings emphasize the substantial health and economic benefits of mRNA-1273 over
BNT162b2 in the high-risk population.

42 Keywords

- 43 Competing interests
- 44 Prof. Dr. Maarten J. Postma and Prof. Dr. Cornelis Boersma received grants and honoraria from various
- 45 pharmaceutical companies, inclusive those developing, producing and marketing vaccines. Tjalke Westra
- 46 and Ekkehard Beck are an employee and shareholder of Moderna, Inc.
- 47 Funding
- 48 Funding for this research was provided by Moderna, Inc.

50 Introduction

51 The COVID-19 pandemic has been a global health crisis of unprecedented proportions, profoundly impacting 52 public health systems and economies across the world¹. Since the onset of the pandemic, vaccines have been 53 the most effective intervention in preventing the spread of the SARS-CoV-2 virus and reducing the clinical 54 burden of COVID-19². Currently, SARS-CoV-2, particularly Omicron and its subvariants, reached an endemic 55 stage in the Netherlands³.

56 Despite the substantial levels of COVID-19 vaccination coverage and immunity resulting from prior 57 infections and vaccinations, the emergence of the Omicron variant in late 2021 triggered a rapid surge in 58 COVID-19 cases, affecting various countries, including the Netherlands. The implementation of a proactive 59 strategy has been critical for maintaining and strengthening immunity across the population. This strategy 60 included the introduction of booster vaccinations with the aim of increasing the durability and effectiveness 61 of protection against COVID-19.

62 The Netherlands launched its COVID-19 booster vaccination campaign in November 2021, initially targeting those aged 18 years and older. By February 2022, eligibility for a second COVID-19 booster was limited to 63 individuals at higher risk, such as those aged 70 and older, residents of nursing homes, adults with Down 64 syndrome, and those with severe immunodeficiency, provided they had completed both their initial 65 66 vaccination series and the booster shot⁴. On September 19, 2022, a new phase of the booster campaign was 67 launched, featuring the use of bivalent COVID-19 mRNA vaccines, namely BNT162b2 (Comirnaty, 68 BioNTech/Pfizer) and mRNA-1273.222 (Spikevax, Moderna)⁵. The Minister of the Netherlands decided, in September 2023, to initiate a structural vaccination program, on the advice of the Health Council^{6,7}. The 69 public vaccination programme were extended to various target groups, including individuals aged 60 and 70 older, medical high-risk groups, pregnant women, and healthcare workers⁸. In October 2023, a new round 71 of vaccinations started, using the BNT162b2 monovalent XBB.1.5 vaccine to target the Omicron XBB lineage 72 that was at the time predominant, thus replacing the previous bivalent vaccine. 73

74	As of April 2023, mRNA-1273 is no longer part of the COVID-19 vaccination programme in the Netherlands;
75	only the monovalent BNT162b2 is being administered ⁹ , despite both mRNA technology-based vaccines being
76	licensed in Netherlands. The vaccines differ in delivery system and dosage, with the mRNA-1273 vaccine
77	containing a higher dosage of active ingredient (50 μ g for the booster) compared to the BNT162b2 vaccine
78	(30 μ g of mRNA for the booster). These differences may impact vaccine effectiveness, as demonstrated in
79	high-risk patients such as older adults, where a meta-analysis considering studies evaluating both primary
80	series and booster of mRNA-1273 (100 and 50 μ g) showed lower risk compared to BNT162b2 (30 μ g) in
81	SARS-CoV-2 infections (risk ratio 0.72) and COVID-19-related hospital admissions (risk ratio 0.65) ¹⁰ .
82	The aim of this study was to estimate the cost-effectiveness of a Fall 2023 COVID-19 booster campaign with
83	the XBB.1.5 updated mRNA-1273 vaccine compared to the XBB1.5 BNT162b2 vaccine in the Netherlands. This
84	can inform the decisions regarding COVID-19 vaccination in 2024 and beyond.
85	Methods
86	Model overview
87	A decision tree-based cost-effectiveness model (Figure 1) was developed ^{11} to estimate the cost-effectiveness of
88	an XBB1.5 updated mRNA-1273.222 vaccination programme from a societal perspective. The analysis
89	covered a one-year time horizon (e.g., October-September), during which the long-term effects of COVID
90	were also accounted for. The primary comparison focused on the XBB1.5 BNT162b2, which is the current
91	standard in the Netherlands, but no vaccination was also included in the analysis. The XBB1.5 updated

vaccines will be referred to as mRNA-1273 and BNT162b2 in the remainder of this manuscript. The model

93 simulates the consequences of infections, including resource utilization, mortality, and their impact on

94 quality of life. The model incorporates the short-term "infection period" and covers immediate infection-

95 related consequences, including infection-related myocarditis, outpatient care, hospitalizations including

96 ICU, and post-hospitalization recovery as well as the "post- COVID" period accounting for any long-term

97 impacts resulting from the COVID-19 infection.





- 99
- Figure 1 Overview of the full model structure 100

101 ICU: Intensive Care Unit; Toll: The outcome does not occur in all cases, but in a percentage of the patients.

102

Model Input 103

- All input parameters of the model can be found in Table 1. Costs were expressed in 2023 price levels and 104
- were not discounted given that the model's time horizon is limited to one year. However, health effects 105
- associated with premature death were considered beyond one year and discounted with 1.5%¹². 106

Target population 107

- 108 The population eligible for a booster vaccination was estimated at 5,922,719 (Table 1) and includes
- individuals aged 60 years and older, and individuals aged 18 to 59 years who are annually invited for 109
- influenza vaccination, including medical-risk groups, healthcare workers and pregnant individuals^{8,13,14}. 110

Vaccine characteristics 111

- mRNA-1273 was compared with no Fall booster and with the BNT162b2 vaccine. The characteristics of both 112
- vaccines can be found in Table 1. The vaccine is administered from October to the end of December aligned 113
- with the Dutch recommendation. Consequently, vaccination coverage is obtained from the Fall vaccination 114

115 campaign 2023¹⁵. For the older adults at risk (18-59 years), the number of vaccinated people in this agegroup per month is divided by the estimated population and has a linear increase over the first two months, 116 increasing from 0% to the coverage in the relevant age group on a monthly basis^{8,13,14} 117 118 The vaccine effectiveness of BNT162b2 against symptomatic infection was derived from a meta-analysis showing a vaccine effectiveness of 65% at baseline against the omicron variant ¹⁶. For the effectiveness 119 against hospitalisation, the risk reduction in hospital admissions in the Netherlands was applied at 77%¹⁷. 120 The vaccine effectiveness of mRNA-1273 against symptomatic infection and hospitalization was assessed by 121 using the effectiveness of BNT162b2 and the relative risk obtained from a meta-analysis^{10,16,17}. This meta-122 analysis assessed the comparative effectiveness of mRNA-1273 versus BNT162b2 in the 50 years and older 123 124 using 24 non-randomized real-world studies¹⁰, in which the relative risk for symptomatic infections and hospitalizations was 0.72 [95% CI 0.62–0.83] and 0.65 [95% CI 0.53–0.79], respectively, favouring mRNA-125 1273. Additionally, the waning rate was determined by analyzing the BNT162b2 vaccine's effectiveness at 126 months 1, 4 and 5, and was considered equal for the mRNA-1273 vaccine¹⁶. 127 Clinical input 128 The baseline risk of infection for COVID-19, or the incidence, was calculated using national hospitalization 129 rates for COVID-19 during the 2022-2023 and 2023-2024 seasons¹⁸, the vaccination coverage¹⁹, Dutch 130 demographics²⁰, and the unvaccinated hospitalization risk. More details can be found in the Supplementary 131 132 Materials. Unvaccinated hospitalization risk was based on historical data from the pandemic²¹, corrected for the decreased severity of Omicron compared to the variants of the early pandemic^{22,23}, see the 133 Supplementary Materials for a detailed description of the calculation. The percentage ICU admissions 134 following hospitalizations of the non-vaccinated per age-group was derived from The National Intensive 135 Care Evaluation (NICE), a foundation that facilitates the registration of COVID-19 patients in Dutch ICU and 136

137 general ward²⁴. The data used covers the period from October 03, 2022, to May 29, 2023. Additionally,

- 138 hospital-based mortality data, for both general ward and ICU admissions, were also derived from The
- 139 National Intensive Care Evaluation ²⁴. For hospital readmission and post-discharge mortality, only data from

the pandemic period were available in the Netherlands, namely 11.70% and 3.80%, respectively^{25,26}. For the 140 proportion not hospitalized, influenza data were applied as no COVID-19 specific data were available²⁷. In 141 addition, following infection, myocarditis can occur depending on age. See the Supplementary Materials for 142 estimates of the myocarditis/pericarditis age-dependent incidence, costs and QALY losses, including a 143 detailed description of the calculation. 144 Neither in the Netherlands nor in Europe is data available on the health-related quality of life associated with 145 symptomatic COVID-19 infections, including not-hospitalized cases, hospital admissions, ICU admissions, 146 and post-covid conditions/long-COVID. As a result, our model incorporated US values²⁸, QALY losses were 147 derived from unpublished data obtained from the Coronavirus Household Evaluation and Respiratory 148 Testing (C-HeaRT) and the Prospective Assessment of COVID-19 in a Community (PACC). Next to the QALY 149 losses, life years lost were also included in the analysis. 150

151 <u>Costs</u>

The actual acquisition price of the mRNA-1273 and BNT162b2 vaccine is unknown as these vaccines are 152 purchased via European tenders and consequently prices are confidential. Nevertheless, the maximum price 153 was assumed to be €77.70 based on the German listprice²⁹. For BNT162b2, the Economically Justifiable Price 154 (EJP) is estimated at a threshold value of 20,000 per QALY, which was the often-used willingness-to-pay 155 (WTP) in the Fall of 2023 in the Netherlands. Early in 2024, a report was published where it was argued 156 that the WTP threshold for public health interventions, including vaccines, should be increased to €50,000 157 per QALY³⁰. This updated threshold was used in this analysis to assess the cost effectiveness of mRNA-1273. 158 Direct costs cover expenses associated with the treatment of COVID-19. In the Netherlands, hospital costs for 159 160 both general ward and ICU care were not specified for COVID-19 but rather derived based on costs for individuals hospitalized with community-acquired pneumonia³¹. Additional healthcare costs were derived 161 162 from the Dutch Costing manual¹². Potential costs in the post-infection period (long-COVID) are €1125 in the first year in the Netherlands³², and only first-year costs are considered due to the limited availability of 163 reliable long-term data and the variability in future healthcare needs. Productivity losses were included for 164

the different health outcomes, as well as for adverse events, considering both the workforce participation
 rate and average daily wages³³.

- 167 <u>Adverse events</u>
- 168 For the adverse events related to the administration of the vaccines, we separated two main categories of
- adverse events. First, injection-related adverse events that are comparable to other vaccines and often are
- 170 not severe and were extrapolated from data related to the herpes zoster vaccine. This dataset provides
- incidence rates and quality-adjusted life year (QALY) losses per adverse event (grade 3 systemic/local and
- severe events)³⁴. For grade 3 adverse events following vaccination, expenses for painkillers were included³⁵.
- 173 Second, for non-reactogenicity, and more severe adverse events, COVID-19 vaccine data were used. The
- occurrence of myocarditis was based on data from the United Kingdom and was specific for both COVID-19
- vaccines included in the analysis³⁶. For myocarditis, we assumed a QALY loss of 0.7, associated with a
- 176 hospital stay duration of 5.3 days (based on the age group 20-45 years), resulting in a QALY loss per case of
- 177 0.0102 (calculated as $0.7/365^{+}5.3$)^{34.37}. Myocarditis-related costs were also based on the hospital length of
- 178 stay¹². For anaphylaxis, Dutch COVID-19 specific incidence data were used³⁸ and an influenza-related QALY
- 179 loss was applied³⁹. Costs per case were based on 1 emergency visit¹².
- 180

181 Table 1 Input parameters

Input			Source
Population		5,922,720	
	18-29 years	323,404	
	30-39 years	268,237	
	40-49 years	248,979	
	50-59 years	298,007	CBS ¹³
	60-64 years	1,181,545	RIVM ¹⁴
	65-69 years	1,031,232	
	70-79 years	1,699,314	
	80+ years	872,002	

Progression of				
COVID-19				
infection				
Incidence	Incidence			
COVID-10	Age- and mont	h-dependent	Supplementary	
00010-19			Materials	
Proportion of				
infected people				
seeking care at	20.60%		7000 rat 2021^{27}	
the general	29.0%		Zeeval 2021	
practitioner				
level				
Omicron-	18-29 years	0.12%		
adjusted	30-39 years	0.35%	De Boer 2022 ²¹	
hospitalization	40-49 years	0.39%	Bast 2021 ⁴⁰	
rates	50-59 years	0.68%	Number 2021	
(unvaccinated)	60-69 years	1.95%	11yberg 2022	
by age	70-79 years	3.86%		
by age	80+ years	20.38%		
Percentage ICU	18-39 years	11.22%		
after	40-59 years	11.72%	RIVIM NICF²⁴	
hospitalization,	60-79 years	9.53%	NUMBER	
by age	80+ years	3.14%		
	18-29 years	0.19%		
	30-39 years	0.57%		
In-hospital	40-49 years	0.85%		
mortality (no	50-59 years	2.10%	RIVIM NICF²⁴	
ICLI) by age	60-64 years	4.09%	NUMBER	
100), by age	65-69 years	7.31%		
	70-79 years	14.2%		
	80+ years	22.29%		
	18-29 years	5.09%		
	30-39 years	5.16%		
In-hospital	40-49 years	8.95%		
mortality	50-59 years	15.05%	RIVIM NICF²⁴	
(ICI) by age	60-64 years	23.95%	NUMINEL	
	65-69 years	33.19%		
	70-79 years	44.58%		
	80+ years	51.87%		
Hospital re-	11.70%		Leijte 2020 ²⁵	
admission rate	1.,0/0		Ramzi 2022 ²⁶	
Post-discharge	3.80%		Ramzi 2022 ²⁶	
Mortality	5.0070			

	Myocarditis			see
	(infection	Age- and sex-dependent	Supplementary	
	related)		Materials	
V	accine Characteri	istics (95%, CI)		
V	accine costs	XBB1.5 mRNA-1273	XBB1.5 BNT162b2	
	Acquisition		Model outcome, reflecting the	
	costs	€77.70	EJP	
	Administration		·	CNDC41
	costs	€12./5		SINPG
V	accine			
e	ffectiveness			
ą	gainst infections			
				Wu 2023 ¹⁶
	Initial vaccine	75% (58-84)	65% (35-80)	Kavikondala
	efficacy	/3/0 (30 04)		2023 ¹⁰
	Monthly	4.58%		Wu 2023 ¹⁶
	waning			
V	accine			
e	ffectiveness			
a	gainst			
h	ospitalization			_
				RIVM ⁴⁷
	Initial vaccine	85%	77%	Kavikondala
	efficacy			2023
	D (f = 4) =] = -			
	Monthly	3.58%		Wu 2023 ¹⁶
-	waning			
F	all booster	Oct – Nov – Dec – Jan		
0			N/	
	18-59 years	5.01% - 7.94% - 10.10% - 11.55%		
	60-64 years	1.00% - 11.00% - 25.00% - 32.0		
	05-09 years	0.00% - 29.00% - 40.00% - 40		
	70-79 years	1.55% - 10.2/% - 50.1/% - 60.6		
_	80+ years 1.30% - 49.11% - 60.25% - 63.31%			
A	Approx Creade C			
1	Any Grade 3	4.000/		Dupper a cost ²⁴
	local adverse	4.90%	Prosser 2021 ⁵¹	
-	Any Crode a			
1	Ally Grade 3	761 06		
1	systemic	7.01%0		
1	auverse events			

Anaphylaxis	0.0009%		RIVM ³⁸	
Myocarditis /				
Pericarditis	4.5 (3.9-4.8) per million doses	2.5 (2.0-2.8) per million doses	Stowe 2023 ³⁶	
(applies to ages		5(1)		
18-39 only)				
Casta				
Costs Direct costs				
Direct costs			Dutch Costing	
(CD vicit)	€40	.31	Manual ¹²	
(Gr VISIC) Hospitalized			Wallua	
			Rozenbaum	
General ward	€6,5	577	2015 ³¹	
ICU	€18.	375	2013	
Hospitalization		575		
recovery			Dutch Costing	
(inpatient follow-	€111	l.17	Manual ¹²	
up)				
Post-infection				
period (long-	€1,1	Fens 2023 ³²		
COVID)				
Myocarditis				
following infection	Age-dep	Supplementary		
		Materials		
Adverse events				
(unit cost)				
Any Grade 3				
local adverse	€0.			
events			Medicijnkosten.	
Any Grade 3			nl 35	
systemic	€0.	24		
adverse events			Datab Casting	
Anaphylaxis	€316.40 (1	ED visit)	Manual ¹²	
			Dutch Costing	
Myocarditis	£2 ∩82 (⊑ 2 n	ursing days)	Manual ¹²	
(18-30vears)	0,002 (.5 1		Dutch	
			Statistics ³⁷	
Indirect costs				
D			See	
Percentage in	Age-dependent		Supplementary	
labor torce			Materials ³³	

		Dutch
Deiluungo	€194.67	Statistics ³³
Daily wage		Dutch Costing
		Manual ¹²
Productivity loss		
estimates (in		
days)		
Vaccine	0.10	One hour,
administration	0.13	assumption
Non-	2.50	Doctmo 200542
hospitalized	3.50	POSUIIA 2005 ⁻
Hospitalized	8.43 (SD 7.51)	Bekker 202343
ICU	16.64 (SD 13.69)	Bekker 202343
Recovery from		
hospitalisation	27	Chopra 2021 ⁴⁴
Post-COVID	11	van Zon 2023 ⁴⁵
Myocarditis		See
(infection-	Age-dependent	Supplementary
induced)		Materials 37
Myocarditis	2	Dutch
(adverse event)	3	statistics ³⁷
Anaphylaxis	1	Dutch
(adverse event)	I	statistics ³⁷
QALY losses		
Baseline utility		
data for the	Ago dependent	
population by age	Age-uqperiderit	
group		
Short-term		
infection period		
Symptomatic	0.006 (0.004-0.008)	Proceer 2022
infection		P1055CI 2023
Hospitalized no	0.027	Process 2022 2^8
ICU	0.027	F1055CI 2023
Hospitalized	0.054	Process 2022 2^8
ICU only	0.054	F1055CI 2023
Hospital	0.007	Equal to
readmission	0.02/	hospitalization
Post-infection		
period (post-		Prosser 2023 28
COVID)		

	Not		Sandmann
	hospitalized	0.032 (0.010-0.049)	2022 ⁴⁶
	Hospitalized	0.12	PHOSP-COVID Collaborative Group ⁴⁷
A	dverse events		
	Any Grade 3		
	local adverse	0.0003	Prosser 2019 ³⁴
	events		
	Any Grade 3		
	systemic	0.0011	Prosser 2019 ³⁴
	adverse events		
	Anaphylaxis	0.020	Fens 2021 ³⁹
	Myocarditis		Prosser 2019 ³⁴
	(vaccine-	0.0102	Dutch
	induced)		Statistics ³⁷

182 Abbreviations: CI, confidence interval; ED, emergency visit; EJP: Economically Justifiable Price; ICU,

183 intensive care unit; SD, standard deviation; QALY, quality-adjusted life years.

184

185 Analysis

The primary analysis considered the cost-effectiveness of mRNA-1273 compared to BNT162b2, expressed as 186

187 an incremental cost-effectiveness ratio (ICER) as costs per QALY, from a societal perspective. For the

188 primary analysis, the price BNT162b2 was estimated using a WTP of €20.000 per QALY compared to no

vaccination, as explained above. Additionally, the price premium of mRNA-1273 compared to BNT162b2 was 189

190 calculated using a WTP of €50.000 per QALY.

191 As stated above, tender prices are confidential in The Netherlands, therefore the mRNA-1273 was estimated

assuming different BNT162b2 prices. In addition, to assess the robustness of the model, a deterministic 192

193 sensitivity analysis was performed, quantifying the impact of specific parameters on the results. The

distributions were varied by 20% of the mean. The 10 most influential parameters were presented in a 194

tornado diagram. In addition, a probabilistic sensitivity analysis was performed to evaluate the uncertainty 195

- in the results when all parameters were varied: involving 1,000 model runs with random samples from the
- 197 underlying parameters distributions. These distributions in were based on the 95% Confidence Intervals
- 198 (95%CI) or, in the absence of such intervals, varied by 20% from the mean. The results were presented in a
- 199 cost-effectiveness plane and a cost-effectiveness acceptance curve (CEAC).
- 200 Next to sensitivity analyses, our study incorporated multiple scenario analyses comparing mRNA-1273 to
- 201 BNT162b2, as detailed in Table 2. These analyses involved varying COVID-19 incidence rates, as the future
- 202 incidence of COVID-19 is unknown as we transition from the pandemic to endemic phase, using both low
- 203 and high estimated values, as explained in the Supplementary Materials. Moreover, one of the scenarios
- 204 explored the incidence of myocarditis following infection and vaccination, utilizing data from the United
- States, where no difference between the vaccines was observed⁴⁸.
- 206

207 Table 2 Scenario analysis

			-
	Base Case Analysis	Scenario Analysis	Source
Scenario 1: Incidence		low value (95% CI),	See Supplementary
COVID-19 (low)		age- and month-	Materials
		dependent.	
Scenario 2: Incidence		high value (95% CI),	See Supplementary
COVID-19 (high)		age- and month-	Materials
		dependent.	
Scenario 3: Vaccine	Infection: 4.58%	Infection: 4.75%	
waning	Inpatient: 3.58% ¹⁶	Inpatient: 1.37 ¹ / ₄₉	
Scenario 4:	BNT162b2: 0.00025%	BNT162b2: 0.0179%	The Vaccine Safety
Myocarditis/	mRNA-1273: 0.00045%	mRNA-1273: 0.0179% ⁵⁰	Datalink and other
Pericarditis excess risk	36		surveillance systems in
following booster			the United States do not
vaccination			indicate a discrepancy
			in
			myocarditis/pericarditis
			rates between the two
			boosters ⁵⁰ .
Scenario 5: Myocarditis/	Willame 2023 + Zuin	Boehmer 2021 ⁴⁸	Boehmer 2021
Pericarditis excess risk	2023 ^{51,52}		represents age-specific
following COVID-19			myocarditis risks
infection			among patients with
			and without COVID-19
			in the United States (see
			Supplementary

					Materials for more details).
Scenario 6: extreme risk	18-29 years	0.12%	18-29 years	0.38%	
hospitalisation 18-60	30-39 years	0.35%	30-39 years	1.11%	
years	40-49 years	0.39%	40-49 years	1.24%	
	50-59 years	0.68%	50-59 years	2.16%	
	De Boer 2023 ²¹		De Boer 2023 ²¹	, with	
			applied odds ra	atio (3.17)	
			for patients wit	th	
			respiratory dis	ease from	
			Vardavas 2021	53	

- Abbreviations: ICU, intensive care unit 208
- 209
- 210 Results
- Base case 211

The public COVID vaccination program targeting 5,922,720 people of which approximately 2,566,389 people 212 213 are being vaccinated substantially reduces the burden of COVID disease. In particular, it was estimated that

110,604 symptomatic infections, 2667 hospitalisations and 604 deaths are averted. The EJP for BNT126b2 214

was determined compared to no vaccination, based on a WTP of €20,000 or €50,000 per QALY, resulted in 215

a price of €38.41 or €92.97 per dose, respectively. 216

When comparing BNT126b2 to mRNA-1273, for the high-risk population, 20,629 symptomatic cases can be 217

218 averted including 924 hospitalizations of which 32 ICU admissions. A total of 207 deaths can be averted.

Excluding the potential additional investment of mRNA-1273, significant reductions in costs are expected, 219

with almost an additional €10 million saved from the healthcare perspective and €2.9 million productivity 220

gained in the population. The health gains relate to 1,506 QALYs gained (Table 3), see Supplementary 221

Materials for more detailed results. While mRNA-1273 is linked to on average 0.12 more vaccination-related 222

- myocarditis cases, 26 more infection-related myocarditis cases can be prevented compared to BNT126b2. 223
- Both vaccination strategies are effective in preventing health effects and costs when compared to no fall 224
- booster vaccination in the Netherlands (Table 3). Considering WTP thresholds of €20,000 and €50,000 per 225

- 226 QALY gained, the maximum price premium of mRNA-1273 compared to BNT126b2 should be €16.72 or
- 227 €34.32 per dose, resulting in total prices per dose of €55.12 and €127.29, respectively.

228

229 Table 3: Health and cost outcomes model

	No fall booster	XBB1.5 mRNA-1273	XBB1.5 BNT162b2 booster
		booster	
Number of	0	2,566,389	2,566,389
vaccinations			
Clinical Outcomes			
(Population			
Total)			
Symptomatic	662,650	531,417	552,046
infections			
GP visits	190,700	152,969	158,794
Hospital	17,523	13,932	14,855
admissions			
ICU	1,146	926	985
admissions			
COVID-19	3,808	2,997	3,204
related deaths			
Myocarditis	828	664	689
due to			
infection			

	Myocarditis as	0,0000	0.2688	0.1404
	iviyocui ulus de	0.0000	0.2000	0.1494
	adverse event			
	Post-COVID	68,520	54,956	57,080
Ç	ALYs & life			
v	ears lost			
	QALYs lost –	7,267	5,823	6,072
	morbidity tota	1		
	morbiency cour			
	Health	4.933	3,951	4,125
	ovorte			
	events			
	Adverse	0	0.5	0.5
	events			
	Infection	16	12	13
]-t]			
	related			
	myocarditi	s		
	Post COVI	D 2,318	1,859	1,933
	QALYs lost –	23,935	19,206	20,463
	. 1.			
	mortality			
	Life years lost	29,519	23,673	25,227
	- 1.1			
F	lealthcare costs	€223,681,906	€537,947,227	€459,703,399
	Vaccination	€0	€359,397,169	€271,318,685
	costs			
	Short-Term	€141,871,309	€112,966,335	€120,258,570
	Infection Costs	3		
	Post COVID	€77,084,489	€61,825,193	€64,214,532

	Infection-	€4,726,108	€3,750,393	€3,903,843
	Related			
	Myocarditis			
	Adverse events	€O	€8,137	€7,768
P	roductivity loss	€153,469,318	€147,860,978	€150,806,404
costs				
	Vaccination	€O	€12,427,432	€12,427,432
	Short-Term	€118,947,828	€104,936,064	€107,250,236
	Infection Costs			
	Post-COVID	€34,185,494	€30,203,779	€30,828,454
	Infection-	€335,996	€291,676	€298,635
	Related			
	Myocarditis			
	Adverse events	€O	€2,026	€1,647

230

231 Sensitivity analyses

- 232 Figure 2 shows the tornado diagram of the deterministic sensitivity analysis. The most influential
- 233 parameters are the vaccination costs, followed by the initial vaccine effectiveness, hospitalization rate, and
- 234 baseline utility values. Figure 2A shows the outcomes assuming a WTP threshold of €20,000 and 2B a WTP
- 235 of €50,000 per QALY gained.

236



239 Figure 2 Tornado plot of the deterministic sensitivity analysis, showing the 10 most influential parameters in the model 240

241

- The CEAC (Figure 3) shows that mRNA-1273 is approximately 40% likely to be cost-effective at the 242
- threshold of €20,000 per QALY gained considering a €16,72 price difference. Considering a threshold of 243
- €50,000/QALY 95% of simulations were found to consider mRNA-1273 cost-effective. The CE plane is 244
- included in the appendix. 245

246

medRxiv preprint doi: https://doi.org/10.1101/2024.09.26.24314420; this version posted September 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



248

249 Figure 3 Cost-Effectiveness Acceptability Curve of a nation-wide vaccination programme for the elderly and risk groups with XBB1.5 mRNA-1273 compared to XBB1.5 BNT126b2 for the Netherlands. Al costs are displayed in 250 251 Euros. ICER: Incremental Cost-Effectiveness Ratio.

252

- Scenario analyses 253
- The scenario analyses are included in Table 4. The scenarios with the low and high incidence have the most 254
- impact on the ICER, ranging from €28,718 per QALY under a high incidence scenario to €96,439 per QALY 255
- when the incidence is low. The impact from other scenarios on the ICER were negligible. 256

257

Table 4 scenario analyses comparing XBB1.5 mRNA-1273 to XBB1.5 BNT126b2 259

	Costs (societal perspective)	Effects (QALYs)	ICER
Base case	XBB1.5 mRNA-1273: €500,591,883 XBB1.5 BNT126b2: €470,492,350 Incremental: €30,099,533	XBB1.5 mRNA-1273: 25,028 XBB1.5 BNT126b2: 26,534 Incremental: 1,506	€19,989 per QALY
Scenario 1: Incidence COVID-19 (low)	XBB1.5 mRNA-1273: €398,556,049 XBB1.5 BNT126b2: €363,886,720 Incremental: €34,670,329	XBB1.5 mRNA-1273: 16,274 XBB1.5 BNT126b2: 17,234 Incremental: 960	€36,100 per QALY
Scenario 2: Incidence COVID-19 (high)	XBB1.5 mRNA-1273: €701,015,632 XBB1.5 BNT126b2: €680,946,352 Incremental: €20,069,280	XBB1.5 mRNA-1273: 43,725 XBB1.5 BNT126b2: 46,442 Incremental: 2,717	€7387 per QALY
Scenario 3: Vaccine waning	XBB1.5 mRNA-1273: €495,378,409 XBB1.5 BNT126b2: €465,278,877 Incremental: €30,099,533	XBB1.5 mRNA-1273: 24,060 XBB1.5 BNT126b2: 25,565 Incremental: 1,506	€19,989 per QALY
Scenario 4: Myocarditis/ Pericarditis excess risk following booster vaccination	XBB1.5 mRNA-1273: €500,657,069 XBB1.5 BNT126b2: €470,558,283 Incremental: €30,098,786	XBB1.5 mRNA-1273: 25,028 XBB1.5 BNT126b2: 26,534 Incremental: 1,506	€19,988 per QALY
Scenario 5: Myocarditis/ Pericarditis excess risk following COVID-19 infection	XBB1.5 mRNA-1273: €501,834,999 XBB1.5 BNT126b2: €471,798,737 Incremental: €30,036,262	XBB1.5 mRNA-1273: 25,032 XBB1.5 BNT126b2: 26,538 Incremental: 1,506	€19,944 per QALY
Scenario 6: extreme risk hospitalisation 18- 60 years	XBB1.5 mRNA-1273: €508,603,585 XBB1.5 BNT126b2: €478,630,618 Incremental: €29,972,967	XBB1.5 mRNA-1273: 25,762 XBB1.5 BNT126b2: 27,275 Incremental: 1,513	€19,812 per QALY

261

262 Discussion

263 In current study, the objective was to conduct a comprehensive cost-effectiveness analysis of a COVID-19 vaccination campaign in the Fall of 2023 with mRNA-1273, compared to BNT162b2, in the high-risk 264 265 population, in the context of the Netherlands. The urgency of this research stems from the need to inform public health decision-makers about the potential benefits and economic implications associated with the 266 adoption of either vaccine in high-risk groups. Both vaccines provide major population health benefits for the 267 health of the population. Our findings show that the XBB.1.5 mRNA-1273 vaccine, is projected to provide 268 269 substantial additional clinical benefits compared to BNT162b2. Specifically, it is estimated that it can prevent an additional 20,629 symptomatic cases, 924 hospital admissions (including 32 ICU admissions), and 207 270 deaths compared to BNT162b2. These health effects translate to €10 million healthcare costs averted (without 271 272 vaccination costs), €2.9 million in productivity gains, and 1,506 total QALYs gained.

For this analysis the price of BNT162b2 was calculated using the EIP and a WTP of €20,000 and €50,000 per 273 QALY. Vaccine prices commonly are subject to tenders, making the comparison of list prices challenging. 274 Confidential discounts on list prices are provided by vaccine manufacturers in tenders, subject to other terms 275 such as predictable supply, long-term agreements and in some cases market exclusivity. Considering the 276 currently available list price of mRNA-1273 of €77.70, COVID-19 vaccination can be perceived as cost-effective 277 against a WTP of €50,000 per QALY as we estimated the EJP of mRNA-1273 at €55.12 or €127.29 per dose 278 considering a WTP of €20,000 and €50,000 per QALY, respectively. The EJP of BNT162b2 was estimated at 279 280 €38.41 or €92.97 per dose, considering both WTP thresholds.

One of the identified risks associated with booster vaccination is the potential occurrence of myocarditis or pericarditis. There is a higher observed risk of myocarditis and/or pericarditis in the population aged 18-39 years, particularly in males aged 18-29 years^{36,54-57}. Specifically, the mRNA-1273 vaccine has been associated with a slightly higher risk of myocarditis and/or pericarditis in comparison to the BNT162b2 vaccine within

285 this population⁵⁸. However, myocarditis risk after booster vaccination is significantly lower compared to the 286 primary series regimen of 2 x 100µg^{36,57}. The high-risk group for myocarditis - as a side effect and complication of infection - i.e. males aged 18-39 with comorbidities, account for a small proportion of the target group for 287 booster vaccination, thus the estimated difference in the number of cases of myocarditis between mRNA-1273 288 289 and BNT162b2 is relatively small in current analysis (0.2688 cases with mRNA-1273 vs 0.1494 cases with BNT162b2). When considering mRNA COVID-19 vaccination risk-benefit with regards to myocarditis, the 290 relative risk for myocarditis is more than seven times higher in patients with COVID-19 compared than those 291 vaccinated⁵⁹, resulting in more infection-related myocarditis averted with the mRNA-1273 booster compared 292 to BNT162b2 (664 cases with mRNA-1273 vs 689 cases with BNT162b2). Considering the public health benefits 293 of vaccination programmes against COVID-19, mRNA COVID-19 vaccines have a positive risk-benefit profile. 294 This is the first cost-effectiveness analysis that estimates the cost-effectiveness of the two vaccines for a Fall 295

vaccination campaign in the Netherlands. Two similar studies have been published for other countries, one for Germany and one for the United States^{49,60}. Both studies used a dynamic modelling approach to estimate the incidence of COVID-19. For Germany, a price premium based on the EJP of ϵ 24.95 per dose was found for mRNA-1273 at a WTP threshold of ϵ 50.000 per QALY⁶⁰. This is highly comparable to our results, which yielded a premium of ϵ 34.32 for mRNA-1273 at the same threshold. For the United States, vaccine prices of \$129.59 and \$120.00 were used for mRNA-1273 and BNT162b2, respectively, yielding an ICER of \$2,100 per QALY from the societal perspective, which is also aligned with our results.

There are some limitations to the present study. First, the challenge of accurately capturing the incidence of COVID-19 poses an important limitation. Therefore, we performed a scenario analysis with lower and higher incidence values than assumed, where we showed that the incidence is a key influential parameter. This stresses the importance for health systems worldwide to implement adequate surveillance systems on pathogens circulating within the populations; it is currently not possible to obtain accurate incidence numbers for COVID-19 in the Netherlands, other than hospital admissions. For the base case analysis, we can compare the number of hospitalizations in the model to the actual reported number of hospitalizations.

310 In the model 14,855 hospitalizations are expected in the XBB1.5 BNT162b2 booster arm, while in the year prior to mid-February 2024, a total of 15,238 hospitalizations have been reported for the Netherlands¹⁸. A 311 second limitation was the absence of head-to-head randomized clinical trials, comparing the vaccine 312 effectiveness of mRNA-1273 and the BNT162b2. Instead, we relied on risk estimates derived from a recent 313 meta-analysis¹⁰. In our analysis, we did not account for any potential wastage of either vaccine resulting 314 from the different presentations, i.e. mRNA-1273 as prefilled syringe and BNT162b2 as either multi-dose or 315 316 single-dose vial. Furthermore, the hospital costs in our study were based on a specific study focusing on hospital admissions with community-acquired pneumonia³¹. This choice may not fully account for the 317 potentially higher costs associated with COVID-19 hospitalizations, such as prolonged hospital stays and the 318 319 use of mechanical ventilation. The duration of hospitalization nowadays, particularly with the new variants, might be shorter compared to the early phases of the pandemic. Regarding the hospitalization rate, 320 estimates from the general population were used²¹, not accounting for the high-risk group targeted in this 321 322 analysis. Applying an extreme increased risk, based on all targeted patients having respiratory disease⁵³, proved to have a marginal impact on the ICER. Lastly, our model exclusively includes vaccination-induced 323 324 myocarditis for the age group of 18-40 years, despite its occurrence in other age groups³⁶. Despite this 325 limitation, our scenario and sensitivity analysis on the incidence of vaccine-induced myocarditis showed a negligible effect on the overall outcome. 326

While the mRNA-1273 is more effective compared to the BNT162b2 vaccine, the Dutch government exclusively purchased the BNT162b2. This suggests missed opportunities for optimizing public health outcomes; our analysis reveals that utilizing mRNA-1273 instead of BNT162b2 could prevent a significant number of additional symptomatic cases as well as reduce hospitalizations and ICU admissions. Therefore, future vaccination recommendations in the Netherlands should consider a more inclusive approach that evaluates and incorporates the comparative (cost-)effectiveness of available vaccine options. This strategy aims to maximize health benefits for the population.

- The cost-effectiveness of mRNA-1273 is dependent on the price of its competition (BNT126b2), and while it 334
- is uncertain whether it is cost-effective at its list price, it is likely to be cost-effective as long as the Dutch 335
- government negotiates a maximum price premium of €34.32 compared to BNT162b2. 336
- 337
- References 338
- 1. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol 339 Genomics. 2020;52(11):549-557. doi:10.1152/physiolgenomics.00089.2020 340
- 2. Network TWERS. Estimated number of lives directly saved by COVID-19 vaccination programs in the 341
- WHO European Region, December 2020 to March 2023, Published online January 13, 342
- 2024:2024.01.12.24301206. doi:10.1101/2024.01.12.24301206 343
- 3. Current information about COVID-19 | RIVM. Accessed February 21, 2024. 344
- https://www.rivm.nl/en/coronavirus-covid-19/current 345
- 346 4. Ministerie van Volksgezondheid W en S. Vervolgadvies tweede boostervaccinatie tegen COVID-19 - Advies - Gezondheidsraad. March 25, 2022. Accessed February 21, 2024. 347
- https://www.gezondheidsraad.nl/documenten/adviezen/2022/03/25/vervolgadvies-tweede-348
- boostervaccinatie-tegen-covid-19 349
- 5. Bivalente covidboosters beschermen tegen omikron | NTvG. October 5, 2022. Accessed November 22, 350 2023. https://www.ntvg.nl/artikelen/bivalente-covidboosters-beschermen-tegen-omikron 351
- 6. Ministerie van Volksgezondheid W en S. Kamerbrief over COVID-19-vaccinaties voor specifieke 352 doelgroepen in het najaar van 2023 - Kamerstuk - Rijksoverheid.nl. September 13, 2023. Accessed 353 February 21, 2024. https://www.rijksoverheid.nl/documenten/kamerstukken/2023/09/13/kamerbrief-354 over-uitvoering-covid-19-vaccinatieronde-voor-specifieke-doelgroepen-in-het-najaar-van-2023 355
- 7. Ministerie van Volksgezondheid W en S. Structureel vaccinatieprogramma tegen COVID-19 Vaccinaties -356 Gezondheidsraad. June 28, 2023. Accessed February 21, 2024. 357
- https://www.gezondheidsraad.nl/onderwerpen/vaccinaties/alle-adviezen-over-covid-19-358
- vaccinaties/structureel-vaccinatieprogramma-tegen-covid-19 359
- 8. Zaken M van A. Coronaprik Vaccinatie tegen het coronavirus Rijksoverheid.nl. December 14, 2020. 360 Accessed November 22, 2023. https://www.rijksoverheid.nl/onderwerpen/coronavirus-361 vaccinatie/aanpak-coronavaccinatie 362
- 9. COVID-19-vaccinatie | LCI richtlijnen. Accessed November 22, 2023. https://lci.rivm.nl/richtlijnen/covid-363 19-vaccinatie 364
- 365 10. Kavikondala S, Haeussler K, Wang X, et al. Comparative Effectiveness of mRNA-1273 and BNT162b2 366 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework. Published online November 22, 2023:2023.11.21.23298832. 367
- 368 doi:10.1101/2023.11.21.23298832

11. Lee A, Jayasundara K, Kohli M, et al. Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in Canada. Published online November 11,

369

- 2023:2023.11.10.23298369. doi:10.1101/2023.11.10.23298369 371 12. Ministerie van Volksgezondheid W en S. Richtlijn voor het uitvoeren van economische evaluaties in de 372 gezondheidszorg - Publicatie - Zorginstituut Nederland. February 29, 2016. Accessed June 20, 2023. 373 https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-374 het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/richtlijn-voor-het-uitvoeren-van-375 economische-evaluaties-in-de-gezondheidszorg.pdf 376 13. StatLine - Prognose bevolking; geslacht en leeftijd, 2023-2070. Accessed November 22, 2023. 377 https://opendata.cbs.nl/statline/#/CBS/nl/dataset/85324NED/table?ts=1686053339042 378 14. Heins M, Korevaar J, Knottnerus B, Hooiveld M. Monitor Vaccinatiegraad Nationaal Programma 379 380 Grieppreventie (NPG) 202. Published online 2021. 381 15. Deelname COVID-19-vaccinatie in Nederland (16 januari 2024) | RIVM. Accessed February 27, 2024. https://www.rivm.nl/documenten/deelname-covid-19-vaccinatie-in-nederland-16-januari-2024 382 16. Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against 383 infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence 384 synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439-452. 385 doi:10.1016/S2213-2600(23)00015-2 386 387 17. Driekwart minder kans op ziekenhuisopname na corona-herhaalprik | RIVM. Accessed March 6, 2024. https://www.rivm.nl/nieuws/driekwart-minder-kans-op-ziekenhuisopname-na-corona-herhaalprik 388 389 18. COVID-19 dataset. Accessed July 20, 2023. https://data.rivm.nl/covid-19/ 390 19. RIVM. COVID-19 ziekenhuis en intensive-care-opnames per vaccinatiestatus in Nederland (opnames 3 oktober 2022 - 29 mei 2023).; 2023. Accessed August 4, 2023. https://www.rivm.nl/documenten/covid-391 392 19-ziekenhuis-en-intensive-care-opnames-per-vaccinatiestatus-in-nederland-10 20. Centraal Bureau voor de Statistiek. Bevolking op 1 januari en gemiddeld; geslacht, leeftijd en regio. 393 Centraal Bureau voor de Statistiek. May 30, 2022. Accessed April 4, 2023. https://www.cbs.nl/nl-394 nl/cijfers/detail/03759ned?dl=39E0B 395 21. de Boer PT, van de Kassteele J, Vos ERA, et al. Age-specific severity of severe acute respiratory syndrome 396 coronavirus 2 in February 2020 to June 2021 in the Netherlands. Influenza and Other Respiratory 397 Viruses. 2023;17(8):e13174. doi:10.1111/irv.13174 398 22.Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the 399
- USA. The Lancet Infectious Diseases. 2021;21(12):1629-1630. doi:10.1016/S1473-3099(21)00685-X 400
- 23. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death 401 associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. 402 The Lancet. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7 403
- 404 24.NICE. Covid-19 infecties op de IC. Accessed November 22, 2023. https://www.stichting-nice.nl/covid-19op-de-ic.jsp 405

406	25. Sterfte en heropname na ziekenhuisopname met covid-19 NTvG. November 20, 2020. Accessed
407	November 22, 2023. https://www.ntvg.nl/artikelen/sterfte-en-heropname-na-ziekenhuisopname-met-
408	covid-19
409	26.Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients;
410	A systematic review and meta-analysis. <i>Am J Emerg Med.</i> 2022;51:267-279.
411	doi:10.1016/j.ajem.2021.10.059
412 413 414	27.Zeevat F, Crépey P, Dolk FCK, Postma AJ, Breeveld-Dwarkasing VNA, Postma MJ. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. <i>Value in Health</i> . 2021;24(1):3-10. doi:10.1016/j.jval.2020.11.002
415	28. Economic Analysis of Vaccination with mRNA Booster Dose against COVID-19 Among Adults.
416	Accessed March 6, 2024. https://stacks.cdc.gov/view/cdc/132890
417	29.Ärzteblatt DÄG Redaktion Deutsches. Angepasster Moderna-Impfstoff ab 1. Oktober bestellbar. Deutsches
418	Ärzteblatt. September 26, 2023. Accessed March 6, 2024.
419	https://www.aerzteblatt.de/nachrichten/146254/Angepasster-Moderna-Impfstoff-ab-1-Oktober-
420	bestellbar
421	30.Polder J, van Exel, Kahlman J, et al. <i>Kennisplatform: Preventie op waarde schatten</i> . ZonMW; 2023.
422	Accessed March 6, 2024. https://www.zonmw.nl/nl/nieuws/kennisplatform-preventie-op-waarde-
423	schatten
424 425 426	31. Rozenbaum MH, Mangen MJJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. <i>Vaccine</i> . 2015;33(28):3193-3199. doi:10.1016/j.vaccine.2015.05.001
427	32. Veel mensen die ziek zijn door post-covid gaan gewoon naar hun werk. Vooral vrouwen en
428	hoogopgeleiden. Zo zit dat. Dagblad van het Noorden. April 13, 2023. Accessed November 29, 2023.
429	https://dvhn.nl/meer/gezond/Een-op-vijf-pati%C3%ABnten-werkt-door-met-post-covid-blijkt-uit-
430	Gronings-onderzoekGezond-is-dat-nietVooral-vrouwen-en-hogeropgeleiden-werken-met-klachten
431	Hoe-kan-dat-28358318.html
432	33.StatLine - Werkzame beroepsbevolking; arbeidsduur, 2003-2022. Accessed November 22, 2023.
433	https://opendata.cbs.nl/#/CBS/nl/dataset/82647NED/table
434	34. Prosser LA, Harpaz R, Rose AM, et al. A Cost-Effectiveness Analysis of Vaccination for Prevention of
435	Herpes Zoster and Related Complications: Input for National Recommendations. <i>Ann Intern Med.</i>
436	2019;170(6):380-388. doi:10.7326/M18-2347
437	35. Nederland Z. TRAMADOL HCL/PARACETAM AUR TAB FILMOMH 37,5/325MG Medicijnkosten.nl.
438	Accessed November 22, 2023.
439	https://www.medicijnkosten.nl/medicijn?artikel=TRAMADOL+HCL%2FPARACETAM+AUR+TAB+FIL
440	MOMH+37%2C5%2F325MG&id=07d21c743d7c5877b89d9ef18330e005
441 442 443 444	36.Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. <i>PLoS Med.</i> 2023;20(6):e1004245. doi:10.1371/journal.pmed.1004245

medRxiv preprint doi: https://doi.org/10.1101/2024.09.26.24314420; this version posted September 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY-ND 4.0 International license .
- 37. StatLine Ziekenhuisopnamen en -patiënten; diagnose-indeling ICD-10 (3-teken niveau). Accessed 445 November 27, 2023. https://opendata.cbs.nl/#/CBS/nl/dataset/84069NED/table 446 38. Ministerie van Volksgezondheid W en S. Nota 15 minuten observatieperiode na COVID-19-vaccinatie -447 Rapport - Rijksoverheid.nl. July 5, 2023. Accessed March 6, 2024. 448 449 https://www.rijksoverheid.nl/documenten/rapporten/2023/07/05/nota-15-minuten-observatieperiodena-covid-19-vaccinatie 450 39. Fens T, de Boer PT, van Puijenbroek EP, Postma MJ. Inclusion of Safety-Related Issues in Economic 451 Evaluations for Seasonal Influenza Vaccines: A Systematic Review. Vaccines (Basel). 2021;9(2):111. 452 doi:10.3390/vaccines9020111 453 Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant 40. 454 in the USA. Lancet Infect Dis. 2021;21(12):1629-1630. doi:10.1016/S1473-3099(21)00685-X 455 41. Vergoeding. SNPG. Accessed November 22, 2023. https://www.snpg.nl/article/griep-ha-456 afronden/declareren-griepvaccinaties/vergoeding/ 457 458 42. Postma MJ, Jansema P, Scheijbeler HWKFH, van Genugten MLL. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine. 2005;23(46-47):5365-459 460 5371. doi:10.1016/j.vaccine.2005.06.007 43.Bekker R, uit het Broek M, Koole G. Modeling COVID-19 hospital admissions and occupancy in the 461 Netherlands. Eur J Oper Res. 2023;304(1):207-218. doi:10.1016/j.ejor.2021.12.044 462 44. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients 463 464 Hospitalized With COVID-19. Ann Intern Med. Published online November 11, 2020:M20-5661. doi:10.7326/M20-5661 465 466 45. van Zon S. ACTION conference. Presented at: April 2023. 46.Sandmann FG, Tessier E, Lacy J, et al. Long-Term Health-Related Quality of Life in Non-Hospitalized 467 468 Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional 469 Comparison With Controls. Clin Infect Dis. 2022;75(1):e962-e973. doi:10.1093/cid/ciac151 470 47.PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID 471 and association with 1-year recovery following hospitalisation in the UK: a prospective observational 472 study. Lancet Respir Med. 2022;10(8):761-775. doi:10.1016/S2213-2600(22)00127-8 473 48. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis 474 Using Hospital-Based Administrative Data - United States, March 2020-January 2021. Morbidity and 475 Mortality Weekly Report. 2021;70(35):1228. doi:10.15585/mmwr.mm7035e5 476 49.Kohli MA, Maschio M, Joshi K, et al. The potential clinical impact and cost-effectiveness of the updated 477 478 COVID-19 mRNA fall 2023 vaccines in the United States. Journal of Medical Economics. 2023;26(1):1532-1545. doi:10.1080/13696998.2023.2281083 479 50. Shimabukuro T. Covid-19 vaccine safety update: primary series in young childre and booster doses in 480 older children and adults. Advisory Committee on Immunization Practices (ACIP). Published online 481 September 1, 2022. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/05-482 COVID-Shimabukuro-508.pdf 483

- 484 51. Zuin M, Rigatelli G, Bilato C, et al. One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis. Can J Cardiol. 2023;39(6):839-844. doi:10.1016/j.cjca.2022.12.003 485 486 52. Willame C, Dodd C, Durán C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. Vaccine. 2023;41(1):251-262. 487 488 doi:10.1016/j.vaccine.2022.11.031 53. Vardavas CI, Mathioudakis AG, Nikitara K, et al. Prognostic factors for mortality, intensive care unit and 489 hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in 490 Europe. European Respiratory Review. 2022;31(166). doi:10.1183/16000617.0098-2022 491 54. Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or pericarditis risk after mRNA COVID-19 492 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 493 2022;40(32):4663-4671. doi:10.1016/j.vaccine.2022.05.048 494 55. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 495 23 Million Residents. JAMA Cardiology. 2022;7(6):600-612. doi:10.1001/jamacardio.2022.0583 496 56. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA 497 Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in 498 499 Ontario, Canada. JAMA Netw Open. 2022;5(6):e2218505. doi:10.1001/jamanetworkopen.2022.18505 57. Hviid A, Nieminen TA, Pihlström N, et al. Booster vaccination with SARS-CoV-2 mRNA vaccines and 500 myocarditis in adolescents and young adults: a Nordic cohort study. European Heart Journal. Published 501 502 online February 15, 2024:ehae056. doi:10.1093/eurheartj/ehae056 58. Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA 503 vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-504 controlled case series analysis in England. PLoS Med. 2023;20(6):e1004245. 505 506 doi:10.1371/journal.pmed.1004245 507 59. Voleti N, Reddy SP, Ssentongo P. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2022;9. Accessed November 508 23, 2023. https://www.frontiersin.org/articles/10.3389/fcvm.2022.951314 509 Joshi K, Scholz S, Maschio M, et al. Clinical impact and cost-effectiveness of the updated COVID-19 510 60. mRNA Autumn 2023 vaccines in Germany. Journal of Medical Economics. 2024;27(1):39-50. 511 doi:10.1080/13696998.2023.2290388 512
- 513





